Fast-Evolving US Cardiac Ablation Industry Affords Multiplying Niche Opportunities, Says Frost & Sullivan

Jun 25, 2014 11:45 JST

Source: Frost & Sullivan

Manufacturers Must Develop Long-Term Contracts With Distributors and Physicians to Strengthen Their Consumer Base

Mountain View, Calif, Jun 25, 2014 - (ACN Newswire) - The increasing prevalence of cardiac arrhythmias and availability of premium-priced innovative technologies are driving the cardiac ablation market in the U.S. Promising technologies, including balloon-based ablation catheter devices such as cryo-balloon, visually-guided laser, and radiofrequency balloon will push the market forward. Image-guidance and mapping technologies are currently under development, some of which are predicted to usher in a new era of effective and personalized atrial fibrillation (AF) care management.

Recent analysis from Frost & Sullivan's Analysis of the US Cardiac Ablation Market finds the market earned revenue of $2.77 billion in 2013 and estimates this to reach $5.75 billion in 2020. The analysis covers catheter ablation, surgical ablation and cardiac mapping.

For complimentary access to more information on this analysis, please visit: http://bit.ly/Uietc3.

AF affects more than 2.5 to 3.0 million people in the U.S. This number is projected to rise rapidly over the next few years. Consequently, with more than 100,000 surgeries likely to be performed, the use of cardiac ablation devices will escalate.

"Strong demand will remain as high success rates and a growing number of studies showcasing the clinical effectiveness of ablation catheters encourage adoption," said Frost & Sullivan Advanced Medical Technologies Research Analyst Swathi Allada. "Future technologies will shift towards indirect measures, such as real-time contact force ablation lesion and assessment of tissue temperature, opening up niche opportunities in the U.S. market."

Conversely, the increasing number of ablation procedures performed will heighten the need to train electrophysiology specialists and physicians, adding to the already high costs of ablation devices and leading to uncertainties in physician reimbursement. Reimbursement issues will remain a significant factor restricting market growth now and in the future. The lack of differentiation in most vendor offerings will further affect uptake in the U.S.

The development of advanced technologies with superior clinical outcomes will be critical to eliminate pricing issues. Manufacturers need to develop long-term contracts and build good rapport with distributors and physicians in hospitals and clinics to fuel sales. Standardization of procedural times too will be crucial to lower costs and improve staffing and scheduling efficiency, thereby attracting patients to safer procedures with superior outcomes.

"Companies should also bolster their marketing campaigns to boost awareness among practitioners in the U.S.," concluded Allada. "Better awareness will enhance reimbursement approval rates for insurance agencies and prompt more patients to seek treatment for symptoms that often go undiagnosed."

Analysis of the US Cardiac Ablation Market is part of the Advanced Medical Technologies (http://www.medtech.frost.com) Growth Partnership Service program. Frost & Sullivan's related studies include: Global Emerging Interventional Cardiac Devices Market, Western and Eastern European Wound Care and Wound Closure Market, Disinfection and Sterilization Equipment Market Trends in Asia-Pacific, and Image-guided Surgery and Robot-assisted Surgery Market in Asia-Pacific. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

-- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

-- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

- Contact Us: Start the discussion http://bit.ly/1wv5HVR
- Join Us: Join our community http://bit.ly/1l95MXb
- Subscribe: Newsletter on "the next big thing" http://bit.ly/1pzzPeQ
- Register: Gain access to visionary innovation http://bit.ly/1pzzOaO

Analysis of the US Cardiac Ablation Market
ND56-54

Contact:
Jennifer Carson
Corporate Communications - North America
P: +1-210-247-2450
E: jennifer.carson@frost.com
LinkedIn: Transform Health Group http://linkd.in/1pLXwT6
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan https://www.facebook.com/FrostandSullivan
http://www.frost.com

Source: Frost & Sullivan